Retraction notice to "A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer" [Gynecol. Oncol. 105 (2007) 780-783] (DOI:10.1016/j.ygyno.2007.02.027);A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer

Gynecologic Oncology

Volumn 105, Issue 3, 2007, Pages 780-783

  Gilani, Mitra Modares ^a   Karimi Zarchi, Mojgan ^a   Ghaemmaghami, Fatemeh ^a   Behtash, Nadereh ^a   Mousavi, Azam Sadat ^a   Ansaripoor, Soheila ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CA125; Optimal cytoreduction; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN;

ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVARY CANCER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL;

EID: 34248387779     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.09.002     Document Type: Erratum

References (19)

1. Memarzadeh, Lee S.B., Berek J.S., and Farias-Eisner R. CA-125 levels are a weak predictor of optimally cytoreductive surgery in patients with advance epithelial ovarian cancer. Int. J. Gynecol. Cancer 13 (2003) 120-124
2. Barlow M., Pazybylkski M., and Schilder Jm. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Int. J. Gynecol. Cancer 16 (2006) 495-500
3. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer. N. Engl. J. Med. 334 (1999) 1-6
4. Griffiths C.T., Parker L.M., and Fuller A.F. Role of cytoreductive surgery treatment in the management of advanced ovarian cancer. Cancer Treat. Rep. 63 (1979) 235-240
5. Hoskins W.J., McGuire W.P., Brady M.F., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170 (1994) 974-979
6. Omura G.A., Brady M.F., Homesley H.D., et al. Long-term follow up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J. Clin. Oncol. 9 (1991) 1138-1150
7. Rubin S.C., Wong G.Y., Curtin J.P., Barakat R.R., Hakes T.B., and Hoskins W.J. Platinum based chemotherapy of high risk stage I epithelial ovarian cancer following comprehensive surgical staging. Obstet. Gynecol. 82 (1993) 143-147
8. Mayer A.R., Chambers S.K., Graves E., et al. Ovarian cancer staging: does it require a gynecologic oncologist?. Gynecol. Oncol. 47 (1992) 223-227
9. Eisenkop S.M., Spirtos N.M., Montag T.W., Nalick R.H., and Wang H.J. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol. Oncol. 47 (1992) 203-209
10. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20 (2002) 1248-1259
11. Barnholtz-Sloan J.S., Schwartz A.G., Munkarah A.R., et al. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am. J. Obstet. Gynecol. 189 (2003) 1120-1127
12. Byrom J., Widjaja E., Redman C.W.E., Jones P.W., and Tebby S. Can pre-operative computed tomography predict resectability of ovarian carcinoma at primary laparotomy?. BJOG 109 (2002) 369-375
13. Bristow R.E., Duska L.R., Lambrou N.C., et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89 (2000) 1532-1540
14. Chi D.S., Venkatraman E.S., Masson V., and Hoskins W.J. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol. Oncol. 77 (2000) 227-231
15. Hacker N.F., Berek J.S., Lagasse L.D., Nieberg R.K., and Elashoff R.M. Primary cytoreductive surgery or epithelial ovarian cancer. Obstet. Gynecol. 61 (1983) 413-420
16. Curtin J.P., Mailk R., Venkatraman E.S., Barakat R.R., and Hoskins W.J. Stage IV Ovarian Cancer. Impact of surgical debulking. Gynecol. Oncol. 64 (1997) 9-12
17. Cooper B.C., Sood A.K., Davis C.S., et al. Preoperative CA-125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet. Gynecol. 100 (2002) 59-64
18. Brockbank E.C., Ind T.E.J., Barton D.P.J., et al. Preoperative predictors of suboptimal cytoreduction in women with clinical evidence of advance primary epithelial ovarian cancer. Int. J. Gynecol. Cancer 14 (2004) 42-50
19. Vergote I., De Wever I., Tjalma W., Van Gamberen M., Decloedt J., and Van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian cancer: a retrospective analysis of 285 patients. Gynecol. Oncol. 71 (1998) 431-436